Zervikales CUP-Syndrom: Diagnostik und Therapie

 

 Buy Article Permissions and Reprints

Abstract

In CUP syndrome (CUP = cancer of unknown primary) there are 1 or more metastases of a primary tumor that cannot be localized despite extensive diagnostics. CUP syndrome accounts for 5% of all human malignancies, making it one of the 10 most common forms of cancer. In addition to inflammatory lymph node enlargement and benign changes such as cervical cysts, lymph node metastases are among the most common cervical masses. Cervical CUP syndrome is a histologically confirmed cervical lymph node metastasis with an unknown primary tumor. In addition to anamnesis, clinical examination and histological confirmation, diagnostics include radiological imaging using PET-CT and panendoscopy with histological primary tumor search. Treatment options include surgical therapy with neck dissection and chemoradiotherapy.

Publication History

Article published online:
02 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Kraywinkel K, Zeißig S. Epidemiologie des CUP-Syndroms in Deutschland. Onkologe 2017; 23: 966-973 DOI: 10.1007/s00761-017-0301-z.
  CrossrefPubMedGoogle Scholar
• 2 Pavlidis N, Briasoulis E, Greco FA. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003; 39: 1990-2005 DOI: 10.1016/s0959-8049(03)00547-1. (PMID: 12957453)
  CrossrefPubMedGoogle Scholar
• 3 Mozet C, Wichmann G, Stumpp P. et al. Zervikales CUP-Syndrom. Die Onkologie 2013; 19 (01) DOI: 10.1007/s00761-012-2315-x.
  CrossrefPubMedGoogle Scholar
• 4 Schroeder L, Pring M, Ingarfield K. et al. HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer. Oral Oncol 2020; 107: 104721 DOI: 10.1016/j.oraloncology.2020.104721. (PMID: 32361566)
  CrossrefPubMedGoogle Scholar
• 5 Werner JA. Lymphknotenerkrankungen im Kopf-Hals-Bereich. Berlin: Springer; 2002
  CrossrefGoogle Scholar
• 6 Moiso E, Farahani A, Marble HD. et al. Developmental deconvolution for classification of cancer origin. Cancer Discov 2022; 12: 2566-2585 DOI: 10.1158/2159-8290.CD-21-1443. (PMID: 36041084)
  CrossrefPubMedGoogle Scholar
• 7 Verginelli F, Pisacane A, Gambardella G. et al. Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nat Commun 2021; 12: 2498 DOI: 10.1038/s41467-021-22643-w. (PMID: 33941777)
  CrossrefPubMedGoogle Scholar
• 8 Kolling S, Ventre F, Geuna E. et al. “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?. Front Oncol 2020; 9: 1546 DOI: 10.3389/fonc.2019.01546. (PMID: 32010631)
  CrossrefPubMedGoogle Scholar
• 9 Zakarneh A, Kaschke O. Zervikales CUP-Syndrom, Was tun bei unklarem Primärtumor? HNO-Nachrichten 6.2003.
  PubMedGoogle Scholar
• 10 Zaunmayr L. Das CUP-Syndrom (Cancer of Unknown Primary) im HNO-Bereich – Vom Primärstaging der Lymphknotenmetastase bis zur Primumdiagnose. Diplomarbeit Universitätsklinik für HNO-Heilkunde, Universität Graz. 2020
  PubMedGoogle Scholar
• 11 Kennel T, Garrel R, Costes V. et al. Head and neck carcinoma of unknown primary. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136 (03) 185-192 DOI: 10.1016/j.anorl.2019.04.002. (PMID: 31005456)
  CrossrefPubMedGoogle Scholar
• 12 https://www.onkopedia.com/de/onkopedia/guidelines/cup-syndrom-krebserkrankungen-mit-unbekanntem-primaertumor/@@guideline/html/index.html
  PubMed
• 13 Mehanna H, Taberna M, von Buchwand C. et al. Prognostic implications of p16 and HPV discordance in oropharygeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol 2023; 24 (03) 239-251 DOI: 10.1016/S1470-2045(23)00013-X.
  CrossrefPubMedGoogle Scholar
• 14 Losa F, Iglesias L, Pane M. et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol 2018; 20: 1361-1372 DOI: 10.1007/s12094-018-1899-z. (PMID: 29808414)
  CrossrefPubMedGoogle Scholar
• 15 van der I Strate, Kazemzadeh F, Nagtegaal ID. et al. International consensus on the initial diagnostic workup of cancer of unknown primary. Crit Rev Oncol Hematol 2023; 181: 103868 DOI: 10.1016/j.critrevonc.2022.103868. (PMID: 36435296)
  CrossrefPubMedGoogle Scholar
• 16 Röhrich M. Positron emission tomography in CUP syndrome. Radiologie 2023; 63 (05) 354-357 DOI: 10.1007/s00117-023-01144-5. (PMID: 37079059)
  CrossrefPubMedGoogle Scholar
• 17 Ling JP, Böhm F, Schuler PJ. et al. Value of PET imaging in Head and neck cancer. HNO 2023; 71 (10) 681-692 DOI: 10.1007/s00106-023-01354-2.
  CrossrefPubMedGoogle Scholar
• 18 Fritz C, Ng JJ, Harris J. et al. Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal. Eur Arch Otorhinolaryngol 2023; 280 (09) 4195-4204 DOI: 10.1007/s00405-023-07997-9. (PMID: 37103581)
  CrossrefPubMedGoogle Scholar
• 19 Maghami E, Ismaila N, Alvarez A. et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO Guideline. J Clin Oncol 2020; 38: 2570-2596 DOI: 10.1200/JCO.20.00275. (PMID: 32324430)
  CrossrefPubMedGoogle Scholar
• 20 Woo S, Becker AS, Do RKG. et al. Impact of (18)F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. Eur J Cancer 2021; 159: 60-77 DOI: 10.1016/j.ejca.2021.09.031. (PMID: 34742159)
  CrossrefPubMedGoogle Scholar
• 21 Krämer A, Bochtler T, Pauli C. et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 228-246 DOI: 10.1016/j.annonc.2022.11.013. (PMID: 36563965)
  CrossrefPubMedGoogle Scholar
• 22 Accessed February 05, 2024 at: www.gesetze-im-internet.de/sgb_5/__135.html
  PubMed
• 23 Ruhlmann V, Ruhlmann M, Bellendorf A. et al. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trail of whole-body PET/MRI versus PET/CT. Eur J Radiol 2016; 85 (11) 1941-1947
  CrossrefPubMedGoogle Scholar
• 24 Jones AS, Phillips DE, Helliwell TR. et al. Occult node metastases in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1993; 250 (08) 446-449
  CrossrefPubMedGoogle Scholar
• 25 Mendenhall WM, Mancuso AA, Parson JT. et al. Diagnostic evaluation of squamous cell carcinoma metastatic to zervikal lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20 (08) 739-744
  CrossrefPubMedGoogle Scholar
• 26 Di Maio P, Iocca O, De Virgilio A. et al. Narrow band imaging in head and neck unknown primary carcinoma: A systematic review and meta-analysis. Laryngoscope 2020; 130 (07) 1692-1700 DOI: 10.1002/lary.28350. (PMID: 31714611)
  CrossrefPubMedGoogle Scholar
• 27 Lapeyre M, Malissard L, Peiffert D. et al. Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary?. Int J Radiat Oncol Biol Phys 1997; 39 (02) 291-296
  CrossrefPubMedGoogle Scholar
• 28 Mendenhall WM, Mancuso AA, Amdur RJ. et al. Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. Am J Otolaryngol 2001; 22 (04) 261-267
  CrossrefPubMedGoogle Scholar
• 29 Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972; 29 (06) 1446-1449 DOI: 10.1002/1097-0142(197206)29:63.0.co;2-c. (PMID: 5031238)
  CrossrefPubMedGoogle Scholar
• 30 Roman KM, Nguyen C, Torabi SJ. et al. Transoral robotic surgery in HPV+ oropharyngeal cancer of unknown primary. Am J Otolaryngol 2023; 45 (81) 104060 DOI: 10.1016/j.amjoto.2023.104060. (PMID: 37832331)
  CrossrefPubMedGoogle Scholar
• 31 Khalil F, Koch M, Iro H. et al. Positive factors on survival of head and neck cancer of unknown primary: what the clinician can do. Acta Otolaryngol 2023; 16: 1-6 DOI: 10.1080/00016489.2023.2265937.
  CrossrefPubMedGoogle Scholar
• 32 Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?. Int J Radiat Oncol Biol Phys 2001; 50 (03) 727-733
  CrossrefPubMedGoogle Scholar
• 33 Mackenzie K, Watson M, Jankowska P. et al. Investigation and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130 (Suppl. 02) S170-S175 DOI: 10.1017/S0022215116000591.
  CrossrefPubMedGoogle Scholar
• 34 Bernier J, Cooper JS, Pajak TF. et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005; 27 (10) 843-850 DOI: 10.1002/hed.20279. (PMID: 16161069)
  CrossrefPubMedGoogle Scholar
• 35 Grau C, Johansen LV, Jakobsen J. et al. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55 (02) 121-129
  CrossrefPubMedGoogle Scholar
• 36 Fakhrian K, Thamm R, Knapp S. et al. Radio(chemo)therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 2012; 188: 56-61
  CrossrefPubMedGoogle Scholar
• 37 Ligey A, Gentil J, Crehange G. et al. Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an onknown primary. Radiother Oncol 2009; 93: 483-487
  CrossrefPubMedGoogle Scholar
• 38 Jensen K, Friborg J, Hansen CR. et al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. Radiother Oncol 2020; 151: 149-151 DOI: 10.1016/j.radonc.2020.07.037. (PMID: 32781011)
  CrossrefPubMedGoogle Scholar
• 39 Cabrera Rodríguez J, Cacicedo J, Giralt J. et al. GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unknown Primary. Crit Rev Oncol Hematol 2018; 130: 51-59 DOI: 10.1016/j.critrevonc.2018.07.006.
  CrossrefPubMedGoogle Scholar
• 40 Chen AM. Management of unknown primary head and neck cancer with radiation therapy in the era of human papillomavirus (HPV): No longer cutting down the tree to get an apple. Radiother Oncol 2023; 14: 109952 DOI: 10.1016/j.radonc.2023. (PMID: 37844736)
  CrossrefPubMedGoogle Scholar
• 41 Bernier J, Domenge C, Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19) 1945-1952 DOI: 10.1056/NEJMoa032641. (PMID: 15128894)
  CrossrefPubMedGoogle Scholar
• 42 Cooper JS, Pajak TF, Forastiere AA. et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19) 1937-1944 DOI: 10.1056/NEJMoa032646. (PMID: 15128893)
  CrossrefPubMedGoogle Scholar
• 43 Müller von der Grün J, Tahtali A. et al. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. Radiat Oncol 2017; 12: 82 DOI: 10.1186/s13014-017-0817-9.
  CrossrefPubMedGoogle Scholar
• 44 Müller von der Grün J, Bon D, Rödel C. et al. Patterns of care analysis for head & neck cancer of unknown primary site: a survey inside the German society of radiation oncology (DEGRO). Strahlenther Onkol 2018; 194: 750-758 DOI: 10.1007/s00066-018-1308-0.
  CrossrefPubMedGoogle Scholar